Inhibrx, (id:6483 INBX)

14.08 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 5:23:33 PM)

Exchange closed, opens in 1 day 16 hours

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About Inhibrx,

Market Capitalization 202.37M

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.